MDL 100250

Drug Profile

MDL 100250

Latest Information Update: 15 Sep 2004

Price : $50

At a glance

  • Originator Aventis
  • Class Analgesics
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 22 May 2002 Discontinued for Pain in USA (unspecified route)
  • 22 Aug 1995 No-Development-Reported for Pain in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top